Mohamed H. Ladha joined Tocagen as vice president, head of commercial in September 2018. In his role, he is responsible for building, overseeing and executing the global commercial strategies for Tocagen’s oncology products upon regulatory approval in the United States and other key markets. Mr. Ladha has over 23 years of experience in the fields of oncology and immunology including leading product development and marketing teams at pharmaceutical and biotechnology companies. He has commercialized eight products for a variety of oncology indications, including TEMODAR® (temozolomide, Schering-Plough/Merck) for glioblastoma, OncoTICE® (BCG, Schering Plough/Merck) for bladder cancer, and ALUNBRIG® (brigatinib, ARIAD/Takeda) for lung cancer, as well as medicines for autoimmune diseases. Most recently he led the U.S. lung cancer portfolio at Takeda Oncology where he was responsible for the launch and commercialization of ALUNBRIG and subsequent pipeline products. Prior to this, Mr. Ladha led the U.S. and global lung cancer portfolio at ARIAD Pharmaceuticals, part of Takeda Oncology since early 2017. Previously, Mr. Ladha was the head of global and U.S. biosimilars at Hospira/Pfizer where he oversaw the launch and commercialization of three biosimilars in oncology and autoimmune diseases. He also held roles in oncology field sales and later led oncology marketing and product commercial development at Schering-Plough and then Merck for nine years.
Prior to joining industry, Mr. Ladha spent five years as a researcher at Harvard Medical School’s Dana-Farber Cancer Institute and co-authored several scientific publications on his cancer research in areas of RAS driven signal transduction pathway and retinoblastoma and cyclin-dependent cell cycle mechanisms. Mr. Ladha received a master’s of public administration in healthcare/international development from Harvard University and a master’s of business administration in marketing and finance from Northwestern University.